Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revance Therapeutics (RVNC)
:RVNC
Holding RVNC?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.5Same Quarter Last Year
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 01, 2018
|% Change Since: -36.33%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in DAXXIFY aesthetic sales and a promising start for its therapeutic launch. Financial guidance has improved, and the company remains in a strong financial position. However, the soft filler market and modest initial therapeutic revenues present challenges. Overall, the positive aspects outweigh the negatives, indicating a generally favorable outlook.Company Guidance
During the second quarter of 2024, Revance Therapeutics provided guidance towards achieving at least $280 million in total net product revenue for the year, with a focus on reaching positive adjusted EBITDA in 2025. The company's net revenue for Q2 was $65.4 million, a 20% increase from the previous year, driven by strong performances from both DAXXIFY and the RHA Collection, despite a soft filler market. DAXXIFY's net product revenue rose to $28.7 million, a 27% year-over-year increase, with aesthetic units sold up by 65%. Meanwhile, the RHA Collection achieved $36.6 million in revenue, marking a 15% increase from the prior year. The company ended Q2 with over 8,000 aesthetic accounts, including more than 4,200 accounts that have ordered DAXXIFY. Revance reported a gross margin of approximately 73% for the quarter, and they continue to expect 2024 GAAP operating expenses to be between $430 million to $450 million, down from previous projections.Strong Growth in DAXXIFY Aesthetic Sales
DAXXIFY aesthetic units sold increased by 65% year-over-year, with net product revenue of $28.7 million, up 27% year-over-year.
RHA Collection Revenue Increase
RHA Collection net product revenue was $36.6 million in Q2 2024, representing a 15% year-over-year increase, despite overall filler market softness.
Therapeutic Launch of DAXXIFY
Commercial launch of DAXXIFY for cervical dystonia in the $2.7 billion U.S. therapeutic neurotoxin market, with promising initial market response.
Improved Financial Guidance
Revance expects 2024 total net product revenue to be at least $280 million, with reduced GAAP operating expenses forecast.
Strong Financial Position
Total net revenue for Q2 2024 was $65.4 million, a 20% increase compared to the same period in 2023.
---
RVNC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RVNC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $5.78 | $3.70 | -35.99% |
| Aug 08, 2024 | $2.95 | $3.53 | +19.66% |
| May 09, 2024 | $4.29 | $3.32 | -22.61% |
| Feb 28, 2024 | $5.66 | $7.14 | +26.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Revance Therapeutics (RVNC) report earnings?
Revance Therapeutics (RVNC) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Revance Therapeutics (RVNC) earnings time?
Revance Therapeutics (RVNC) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RVNC EPS forecast?
RVNC EPS forecast for the fiscal quarter 2024 (Q4) is -0.26.
---